ArticleAntimicrobial agents and chemotherapy2003
In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 250 citations in OpenAlex.
- Enrofloxacin treatment alters cecal microbiota and metabolites and selects for fluoroquinolone-resistantMicrobiology spectrum · 2026Article
- Virulence and Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Article
- WGS-based surveillance for Campylobacter spp. in human infections and chicken meat production in Italy (2023).BMC microbiology · 2025Article
- Growth rates and metabolic traits differ by diarrhoeal manifestation inJournal of medical microbiology · 2025Article
- The Global Challenge ofTropical medicine and infectious disease · 2025Review
- Review
- WQ-3810, a fluoroquinolone with difluoropyridine derivative as the R1 group exerts high potency against quinolone-resistantMicrobiology spectrum · 2024Article
- Fluoroquinolone-resistantJAC-antimicrobial resistance · 2024Article
- Emergence of Plasmid-Mediated Quinolone Resistance (PMQR) Genes inAntibiotics (Basel, Switzerland) · 2024Article
- Insights on the genomic diversity, virulence and resistance profile of a Campylobacter jejuni strain isolated from a hospitalized patient in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Article
- Genetic Diversity and Resistome Analysis ofAntibiotics (Basel, Switzerland) · 2023Article
- Comparative Studies of Antimicrobial Resistance inFoods (Basel, Switzerland) · 2023Article
- Different stages of the infection cycle are enriched forMicrobiology (Reading, England) · 2023Article
- Whole-Genome and Plasmid Comparative Analysis of Campylobacter jejuni from Human Patients in Toyama, Japan, from 2015 to 2019.Microbiology spectrum · 2023Article
- Growth kinetics and fitness of fluoroquinolone resistant and susceptibleFrontiers in veterinary science · 2023Article
- Antibiotic resistance, plasmids, and virulence-associated markers in human strains ofFrontiers in microbiology · 2023Article
- Conformational dynamics and putative substrate extrusion pathways of the N-glycosylated outer membrane factor CmeC from Campylobacter jejuni.PLoS computational biology · 2023Article
- Development of Fluoroquinolone Resistance through Antibiotic Tolerance in Campylobacter jejuni.Microbiology spectrum · 2022Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enrofloxacin treatment of chickens infected with fluoroquinolone(FQ)-sensitive Campylobacter promoted the emergence of FQ-resistant Campylobacter mutants which propagated in the intestinal tract and recolonized the chickens. The recovered isolates were highly resistant to quinolone antibiotics but remained susceptible to non-FQ antimicrobial agents. Specific single-point mutations in the gyrA gene and the function of the CmeABC efflux pump were linked to the acquired FQ resistance. These results reveal that Campylobacter is hypermutable in vivo under the selection pressure of FQ and highlight the need for the prudent use of FQ antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.